fuch endothelial corneal dystrophy fecd epidemiology forecast insight

DelveInsight’s ‘Fuchs Endothelial Corneal Dystrophy (FECD) – Epidemiology Forecast—2034’ report delivers an in-depth understanding of Fuchs Endothelial Corneal Dystrophy (FECD), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Fuchs Endothelial Corneal Dystrophy (FECD) Disease Understanding

Fuchs Endothelial Corneal Dystrophy (FECD) or Fuchs’ endothelial dystrophy is a defect of the cornea of the eye, where endothelial cells degenerate/get damaged. It can be either sporadic or inherited in an autosomal dominant manner. Fuchs’ dystrophy is characterized by the swelling of the cornea, which leads to glare, halo, and reduced visual acuity. In some cases, it can lead to corneal blindness.

FECD is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients and is more prominent in females than males. Deposits called guttae are generally detectable during an eye exam. They usually form in the middle of the cornea and eventually spread throughout the cornea. These guttae contribute to the ongoing cell death within the cornea, leading to worsening vision problems. Tiny blisters may develop on the cornea, which can burst and cause eye pain.

Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) patients are increasing in 7MM during the study period, i.e., 2021-2034.

The disease epidemiology covered in the report provides historical as well as forecasted Fuchs Endothelial Corneal Dystrophy (FECD) symptoms epidemiology segmented as the Prevalent Cases of Fuchs Endothelial Corneal Dystrophy (FECD), Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD), and Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD). The report includes the prevalent scenario of Fuchs Endothelial Corneal Dystrophy (FECD) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology

The epidemiology segment also provides the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD) in the 7MM were 17,386,186 in 2020 and are expected to grow at a CAGR of 0.66% during the study period.
• As per the estimates, the United States has the largest prevalent population of Fuchs Endothelial Corneal Dystrophy (FECD).
• Among the EU5 countries, Germany had the highest prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD), followed by Italy. On the other hand, Spain had the lowest incident cases with 1,258,137 cases in 2020.

Scope of the Report

• The Fuchs Endothelial Corneal Dystrophy (FECD) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Report and Model provide an overview of Fuchs Endothelial Corneal Dystrophy (FECD) ’s risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into Fuchs Endothelial Corneal Dystrophy (FECD)’s historical and forecasted patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Fuchs Endothelial Corneal Dystrophy (FECD).
• The report provides the segmentation of the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology by the prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) in 7MM.
• The report provides the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology segmentation by Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD) in 7MM.
• The report provides the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology segmentation by Gender-specific cases associated with Fuchs Endothelial Corneal Dystrophy (FECD) in 7MM.

Report Highlights

• 10-year Forecast of Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology
• 7MM Coverage
• Prevalent cases of Fuchs Endothelial Corneal Dystrophy (FECD)
• Gender-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD)
• Age-specific Cases of Fuchs Endothelial Corneal Dystrophy (FECD)

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population about Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the key findings of the Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of Fuchs Endothelial Corneal Dystrophy (FECD) patients across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2021-2034)?
• What are the disease risk, burden, and unmet needs of Fuchs Endothelial Corneal Dystrophy (FECD)?
• What are the currently available treatments for Fuchs Endothelial Corneal Dystrophy (FECD)?

Reasons to buy

The Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Fuchs Endothelial Corneal Dystrophy (FECD) market.
• Quantify patient populations in the global Fuchs Endothelial Corneal Dystrophy (FECD) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Fuchs Endothelial Corneal Dystrophy (FECD) therapeutics in each of the markets covered.
• Understand the magnitude of the Fuchs Endothelial Corneal Dystrophy (FECD) population by its prevalent cases.
• Understand the magnitude of the Fuchs Endothelial Corneal Dystrophy (FECD) population by Gender-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD).
• Understand the magnitude of the Fuchs Endothelial Corneal Dystrophy (FECD) population by Age-specific cases of Fuchs Endothelial Corneal Dystrophy (FECD).
• The Fuchs Endothelial Corneal Dystrophy (FECD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Fuchs Endothelial Corneal Dystrophy (FECD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population